Table 2

Central subfield thickness (μm) at different timepoints

Month 0Month 1Month 7Month 13Month 24
Control
Baseline (mean)763.3
95% CI687.4 to 839.3
Change from month 1−493.9−470.7−494.6
95% CI−581.1 to −406.58−557.9 to −383.38−581.9 to −407.34
P value<0.0001<0.0001<0.0001
Functioning L-CRA
Baseline (mean)700.6
95% CI637.9 to 763.3
P value*0.20
Change from month 1−340.9−325.5−365.1
95% CI−436.8 to −244.93−421.4 to −229.56−461.0 to −269.14
P value<0.0001<0.0001<0.0001
Difference cf control−208.0−55.0−62.8−78.5
95% CI−314.4 to −101.56−161.5 to 51.42−169.3 to 43.59−184.9 to 27.97
P value<0.00010.310.250.15
Non-functioning L-CRA
Baseline (mean)774.6
95% CI605.7 to 943.5
P value*0.88
Change from month 1−602.8−574.2−388.4
95% CI−813.0 to −392.60−784.4 to −364.00−598.6 to −178.20
P value<0.0001<0.00010.0004
Difference cf control−17.9−126.8−121.488.3
95% CI−203.6 to 167.85−312.5 to 58.91−307.1 to 64.31−97.4 to 274.07
P value0.850.180.200.35
  • *Two-sample t-test for difference in means (sham+ranibizumab vs L-CRA+ranibizumab (functioning and non-functioning groups)).

  • cf, compared with; L-CRA, laser-induced chorioretinal anastomosis.